About the project

About Intrasigna ATLAS.

A structured, evidence-graded reference for clinical research peptides — built to be read by informed consumers, clinicians, and researchers at three different depths.

What ATLAS is

Intrasigna ATLAS is a peptide knowledge base. Each monograph follows the same architecture — identity and at-a-glance summary, mechanism of action, dosing architecture, combinations and stacking, safety and contraindications, key studies, related peptides, and a graded reference list. The goal is a single, consistent place to understand what a peptide is, what the evidence actually shows, and where the open questions are.

The three-layer depth model

Every monograph can be read at three levels so the same page serves very different readers:

How evidence is graded

Claims across ATLAS carry an evidence grade so confidence is explicit rather than implied:

Many compounds in the index are investigational, unapproved, or sold for research use only. Where that is the case, the dosing sections are explicitly a hypothesis layer drawn from preclinical and community practice-pattern data — not validated clinical regimens.

Editorial stance

ATLAS does not sell peptides and does not recommend that anyone use them. It summarizes published science and regulatory status, grades the strength of that evidence, and routes readers to primary sources so they can verify and go deeper. Decisions about whether a peptide is appropriate, legal, or safe for a given person belong to that person and a qualified clinician.

Tools

Alongside the monographs, ATLAS offers a reconstitution calculator, a peptide comparison tool, and a glossary. These are educational aids, not clinical software.

← Back to the directory